Pharmaceutical Marketing, the FDA and Free Speech
January 5, 2016
The U.S. Justice Department and state attorneys general have repeatedly used the threat of prosecutions for drugmakers touting off-label uses of pharmaceuticals to wring billions of dollars in settlements, fines and civil damages from them. But now drugmakers are seizing on a Second Circuit court decision to block future extractions, writes NCPA Senior Fellow Thomas Hemphill.
Browse more articles on Health Issues